Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Iterum Therapeutics ( (ITRM) ) has issued an announcement.
On March 27, 2026, Iterum Therapeutics filed a petition in Ireland’s High Court to wind up the company and had Teneo’s Damien Murran and Jennifer McMahon appointed as joint provisional liquidators for the parent and its Irish subsidiary, with a hearing scheduled for April 13, 2026 that could lead to the company’s dissolution. The move immediately shifted executive authority from the board to the liquidators, triggered an event of default on Iterum’s royalty-linked notes with higher default interest and potential litigation for payment, prompted the resignation of the CEO and CFO, and set the stage for a broader wind-down of its U.S. and Bermuda subsidiaries and a likely withdrawal of ORLYNVAH from the U.S. market after failed strategic alternatives, Nasdaq compliance issues and constrained capital options.
The most recent analyst rating on (ITRM) stock is a Hold with a $0.31 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.
Spark’s Take on ITRM Stock
According to Spark, TipRanks’ AI Analyst, ITRM is a Neutral.
The score is held down primarily by weak financial fundamentals (minimal revenue, persistent losses, cash burn, and negative equity) and bearish technicals (price below major moving averages with negative MACD). The earnings call adds some support due to early launch traction and 2026 revenue guidance, but this is tempered by the need for additional capital, while the Nasdaq listing compliance issue adds further downside risk.
To see Spark’s full report on ITRM stock, click here.
More about Iterum Therapeutics
Iterum Therapeutics is a specialty pharmaceutical company focused on developing and commercializing next-generation oral and IV antibiotics targeting multi-drug resistant pathogens in both community and hospital settings. Its lead asset is sulopenem, including ORLYNVAH, an FDA-approved oral sulopenem product for certain uncomplicated urinary tract infections in adult women with limited alternative treatments.
Average Trading Volume: 1,051,215
Technical Sentiment Signal: Sell
Current Market Cap: $9.3M
See more insights into ITRM stock on TipRanks’ Stock Analysis page.